Expert view – The Octet HTX system: enabling multi-purpose screening of therapeutic biologics during development
Posted: 12 December 2019 | ForteBio | No comments yet
Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are the future of the industry, yet despite this, monoclonal antibody (mAb) development remains a dominant focus.
A recent market survey targeting antibody therapeutics professionals in pharma, biotech, academia, CDMOs and CROs found that 81 percent of respondents were involved in mAb development, with the main development challenges encountered at the discovery and target identification stage. Most respondents to the survey indicated that the industry needs technologies that can more accurately identify lead molecules.
Related topics
Antibodies, Assays, Drug Discovery Processes, Screening
Related organisations
ForteBio
